AGIO — Agios Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.21bn
- $1.59bn
- $54.03m
Brief: Agios announces topline results from RISE UP phase 3 trial of Mitapivat in sickle cell disease
Agios sinks as sickle cell drug misses pain crisis goal
Agios Pharma Q3 revenue beats expectations
U.S. STOCKS ON THE MOVE- SLB NV, Bank OZK, Gilead Sciences
U.S. STOCKS ON THE MOVE- Oklo, Boston Scientific, Agios
Agios rise after European drug regulator panel issues positive opinion for blood disorder drug
U.S. STOCKS ON THE MOVE- Shoe Carnival, Leidos Holdings, copper miners
U.S. STOCKS ON THE MOVE- Gap, Aquestive Therapeutics, Lumentum
Agios plunges after FDA delays expanded approval of blood disorder drug
Agios plunges after FDA delays expanded approval of blood disorder drug
Agios Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Agios Pharmaceuticals Q2 revenue beats estimates
Brief: Agios Appoints Dr. Jay Backstrom To Board Of Directors
Agios Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
U.S. RESEARCH ROUNDUP-Domino's Pizza, Prologis, Springworks Therapeutics
U.S. STOCKS ON THE MOVE-Starbucks, Bristol Myers Squibb, Home Depot
U.S. STOCKS ON THE MOVE-BioMarin, Azul, Sun Communities
U.S. STOCKS ON THE MOVE- Twilio, Bath & Body Works, Wingstop
H.C. Wainwright starts Agios Pharmaceuticals coverage with 'buy'